These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes? Padron E Hematology Am Soc Hematol Educ Program; 2015; 2015():349-54. PubMed ID: 26637742 [TBL] [Abstract][Full Text] [Related]
7. Topics in pediatric leukemia--myelodysplastic and myeloproliferative disorders of childhood. Lasky J; Sakamoto KM MedGenMed; 2005 Mar; 7(1):21. PubMed ID: 16369326 [No Abstract] [Full Text] [Related]
8. Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes. Kuykendall AT; Tokumori FC; Komrokji RS Hematol Oncol Clin North Am; 2021 Apr; 35(2):337-352. PubMed ID: 33641873 [TBL] [Abstract][Full Text] [Related]
11. Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies. Pardanani A; Drake MT; Finke C; Lasho TL; Rozell SA; Jimma T; Tefferi A Am J Hematol; 2011 Dec; 86(12):1013-6. PubMed ID: 22086864 [TBL] [Abstract][Full Text] [Related]
12. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Platzbecker U; Fenaux P; Adès L; Giagounidis A; Santini V; van de Loosdrecht AA; Bowen D; de Witte T; Garcia-Manero G; Hellström-Lindberg E; Germing U; Stauder R; Malcovati L; Sekeres MA; Steensma DP; Gloaguen S Blood; 2019 Mar; 133(10):1020-1030. PubMed ID: 30404811 [TBL] [Abstract][Full Text] [Related]
13. The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Bain BJ Leuk Lymphoma; 1999 Aug; 34(5-6):443-9. PubMed ID: 10492067 [TBL] [Abstract][Full Text] [Related]
14. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment]. Harada Y; Harada H Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632 [TBL] [Abstract][Full Text] [Related]
15. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Tefferi A; Cervantes F; Mesa R; Passamonti F; Verstovsek S; Vannucchi AM; Gotlib J; Dupriez B; Pardanani A; Harrison C; Hoffman R; Gisslinger H; Kröger N; Thiele J; Barbui T; Barosi G Blood; 2013 Aug; 122(8):1395-8. PubMed ID: 23838352 [TBL] [Abstract][Full Text] [Related]
16. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study. Osca-Gelis G; Puig-Vives M; Saez M; Gallardo D; Lloveras N; Guàrdia R; Marcos-Gragera R Leuk Lymphoma; 2015 Apr; 56(4):896-902. PubMed ID: 25058372 [TBL] [Abstract][Full Text] [Related]
17. Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO. Kuykendall AT; Padron E Curr Hematol Malig Rep; 2019 Dec; 14(6):543-549. PubMed ID: 31776774 [TBL] [Abstract][Full Text] [Related]
19. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes. Tiu RV; Sekeres MA Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705 [TBL] [Abstract][Full Text] [Related]
20. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. Gorak EJ; Otterstatter M; Al Baghdadi T; Gillis N; Foran JM; Liu JJ; Bejar R; Gore SD; Kroft SH; Harrington A; Saber W; Starczynowski D; Rollison DE; Zhang L; Moscinski L; Wilson S; Thompson J; Borchert C; Sherman S; Hebert D; Walker ME; Padron E; DeZern AE; Sekeres MA Blood Adv; 2023 Oct; 7(20):6120-6129. PubMed ID: 37552083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]